Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.74 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.74 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.68 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | HTR7 | P34969 | 2/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098942 | 0.91 | GRIN2B (0.62) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL7097193 | 0.91 | GRIN2B (0.62) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL7099313 | 0.87 | GRIN2B (0.57) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL5333493 | 0.86 | CHRNA7 (0.60) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL1388535 | 0.85 | GRIN2B (1.00) | GRIN2BGRIN1GRIN2AGRIN2CDRD4 | |
| SCHEMBL7099047 | 0.84 | GRIN2B (0.70) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL5335558 | 0.84 | CHRNA7 (0.58) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL5337358 | 0.83 | CHRNA7 (0.62) | GRIN2BGRIN1HTR1AHTR7CHRNA7 | |
| SCHEMBL7099798 | 0.83 | GRIN2B (0.54) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A | |
| SCHEMBL5334974 | 0.83 | CHRNA7 (0.57) | GRIN2BGRIN1GRIN2AGRIN2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | claimed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | claimed |
| EP-1235798-A4 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | disclosed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1235798-A1 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001032615-A1 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | GRIN1, GRIN2A, GRIN2B | GRIN2B 3/4885GRIN1 1/4885GRIN2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.